Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. - Test2 - elhamkhani - TriplyDB

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q34789249

about

Hybrid spreading mechanisms and T cell activation shape the dynamics of HIV-1 infection Immune activation and inflammation in HIV-1 infection: causes and consequences Potential use of rapamycin in HIV infection Long-term clinical, immunologic and virologic impact of glucocorticoids on the chronic phase of HIV infection Limited durability of viral control following treated acute HIV infection Targeting the latent reservoir to achieve functional HIV cure Barriers to HIV Cure.Safety of hydroxyurea in the treatment of HIV infection.The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.Host-based antipoxvirus therapeutic strategies: turning the tables The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication T cell activation but not polyfunctionality after primary HIV infection predicts control of viral load and length of the time without therapy.Liver transplantation in HCV/HIV positive patients.Pathogenesis and treatment of HIV infection: the cellular, the immune system and the neuroendocrine systems perspective.HIV-associated chronic immune activation.High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells.Reciprocal regulation of the nuclear factor of activated T cells and HIV-1.Solid organ transplantation in HIV-infected recipients.Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1.Kidney transplantation in HIV-infected patients.Toll-like receptor signaling in HIV-1 infection: a potential target for therapy?Kidney disease in children and adolescents with perinatal HIV-1 infection.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Immune activation and collateral damage in AIDS pathogenesis.CD 4+ T cells in the pathobiology of neurodegenerative disorders.Renal transplantation between HIV-positive donors and recipients justified.Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs.Liver transplantation in HIV-positive patients.Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.Functional avidity: a measure to predict the efficacy of effector T cells?Solid organ transplants in HIV-infected patients.Update on antiretroviral treatment during primary HIV infection.Immunosenescence and hurdles in the clinical management of older HIV-patients.The immune response to AIDS virus infection: good, bad, or both?Renal transplantation in HIV patients: A series of four cases.A computational study identifies HIV progression-related genes using mRMR and shortest path tracing.

P2860

Q21092519-FD811E40-8056-4761-9CA5-C9FFC39588AE Q22252860-37056625-AB3F-45C7-8BEB-24A4D2509F57 Q24606795-AACBEAA8-E970-49DC-B2B0-CB24E292A337 Q24799835-96E7FAAC-869B-4844-B245-501B7F0CB8C6 Q24804986-B199C6CC-230C-4BF0-B8BF-DD63B04BE663 Q26745923-B6EF706B-5493-40E8-84C8-C1E38064AE7A Q30245414-38D2BCC8-B3F0-4E86-B0C0-B5B3BB45A8CB Q30946270-C41E0E8D-10FF-450F-B80C-5BBC9BA56137 Q33776495-3BED54CC-52DA-4020-900F-66E33BDA41B6 Q33777910-7366074B-F6D7-46BD-B1EA-0196CAA1CDBD Q34141571-36A94A29-24D0-4013-AA88-000166B968F1 Q34510458-09C3A141-0D5B-41A2-8A81-B0EE7A48E549 Q34640985-4900C232-12F2-476C-832A-DE799D3CDAAF Q34650866-DFB12C7E-CCCB-417C-AD10-0E9D432F512C Q34653277-8BCE0993-36C8-45C8-BEC8-67A5F1858B4B Q34763977-BA4E4F9B-CCE7-4D39-9D25-42ECD647716A Q34819446-ACFC11A6-AAF6-4318-B53F-14DA8B9E1BF1 Q35648552-D4E04CD0-CFC1-43BF-8D5F-CE5888E8B124 Q35791794-7F8A4361-91B8-4A1C-A5AF-D50317C3B245 Q35918353-52EC2B0C-4062-45AA-93DA-8BEEA50F1CBA Q36362752-10F4E159-2032-4C98-A847-CB63FC9D2236 Q36839684-885B818A-EC58-4E4F-9274-E2E5F1143C8F Q36942310-85F0E250-42DC-4F2E-A5C5-575EC1DDE4CF Q37122279-84A3DD25-4237-4C64-8CC1-94C8BD3BE2C5 Q37199493-E3836E02-6400-4889-A894-AD78A50B462C Q37228055-857BE12E-3BC0-433E-BF27-9BF294A1C1DB Q37401425-8A5B065B-587C-4EFC-B7F1-06DFA9479EEB Q37615893-7C39D44A-527A-48D8-9BC8-E7D0C2301C6C Q37636486-510B1176-9065-422B-B8FA-CB6FCF81C2AE Q37837963-9A145AA2-61B5-4C7D-9B9A-84654C3B28DF Q38066211-FD57287F-9D7C-4605-84E6-7B03F488357C Q38124737-67E4F029-13D3-43DE-A7D2-2A65DC0D6019 Q38209874-0D451FBB-70DF-46C7-8EF5-DD0E5E12F203 Q39170367-A617EE89-3E11-42A0-84BC-5EB2179CE6DE Q40643992-FF5A5287-DA35-4855-A962-00761C0DC132 Q42138200-42AFE1AB-DB69-4BEB-B9E7-FBB3B1A0D695 Q42254960-81F500C3-1D05-47E3-8D4E-D76645D91E41

P2860

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.

http://www.wikidata.org/entity/Q34789249

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@ast

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@en

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@nl

type

label

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@ast

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@en

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@nl

prefLabel

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@ast

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@en

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@nl

P1433

Q34789249-115C6E4B-58F2-4820-939E-7D53518FD7A9

P1476

Q34789249-BDAD76F1-FB1F-4995-AE6D-5D9AB8EE0B9D

P2093

Q34789249-122D31DB-6DBF-4588-8790-40A066C4AE82

Q34789249-37C062B5-D2AD-420A-84CC-C60FEA9C1FF5

Q34789249-3A0F3E10-A38E-4473-BDFD-9B09A494D1E9

Q34789249-3C4FEEA4-A4DC-4136-B36D-B5F0FABBDF80

Q34789249-81B0387A-829F-4B38-A48E-C4B579A95B62

Q34789249-8803BF29-F938-40F9-A14D-ECAA063AE5F0

Q34789249-BBC24079-0230-408B-80BC-764757E3420A

Q34789249-EE893AE9-B2B2-4225-B4A4-0B153E3429C8

P2860

Q34789249-0080F88F-5946-4F39-8EBA-1ABAD34A813C

Q34789249-0AA7B46C-8B7F-483F-BDAB-F9D65243ED34

Q34789249-0C4B7CE4-6254-4439-8390-DC4F22F70D78

Q34789249-136C2320-1CDB-4000-8DB5-A6A927039BFB

Q34789249-16239364-2045-4ED3-9C0D-EB5B56911C5E

Q34789249-1C2BD069-FE0A-45B8-A217-98135F0CF054

Q34789249-1FEE3F97-FAC4-424C-9221-8CA078B01783

Q34789249-2016FF3C-1D95-4177-9BF2-BF6D5402E090

Q34789249-20FC0110-4D86-4362-8DDB-0BBDBAB873CC

Q34789249-26676C2A-FC43-4E09-957B-1FFB4A29B922

P304

Q34789249-752D3727-084E-4847-93F1-F971E8C31B23

P31

Q34789249-B0BF6C42-6F8C-463D-97F4-BDC017ADE328

P356

Q34789249-08912CCE-825F-4E60-B1C1-E4BFA2A8EC02

P407

Q34789249-B4D6E22D-8FF5-4D39-8FB1-5489699628A3

P433

Q34789249-4FCBDB88-D48E-4386-8493-3A33E54FBB6E

P478

Q34789249-5F91D786-5BC2-40BE-BCC5-50530BDDF164

P50

Q34789249-0665DFFD-D743-48CB-AF9A-138D45A85145

Q34789249-433030CB-B536-4D66-BF84-3743CD1DA603

Q34789249-9E05216D-C1DB-4151-A0FB-870EE6EFB4D3

P577

Q34789249-92838011-4397-43DC-89D7-C80BFDDEF57D

P698

Q34789249-8E7BE290-E86E-42D9-B4FC-07F8552BE187

P921

Q34789249-6373450A-FDE7-46A8-997B-D9E0F5F75F8C

P932

Q34789249-A13083B3-9A84-4EF0-8D66-336D37403D48

P356

P1433

Journal of Clinical Investigation

P1476

Treatment of primary HIV-1 inf ...... active antiretroviral therapy.

@en

P2093

Alexandre Harari

http://www.w3.org/2001/XMLSchema#string

Brunella Capiluppi

http://www.w3.org/2001/XMLSchema#string

Donatella Ciuffreda

http://www.w3.org/2001/XMLSchema#string

G Paolo Rizzardi

http://www.w3.org/2001/XMLSchema#string

Jean-Philippe Chave

http://www.w3.org/2001/XMLSchema#string

Kim Ellefsen

http://www.w3.org/2001/XMLSchema#string

Patrick Champagne

http://www.w3.org/2001/XMLSchema#string

Pierre-Alexandre Bart

http://www.w3.org/2001/XMLSchema#string

P2860

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

Latent reservoirs of HIV: obstacles to the eradication of virus

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure

Phenotypic analysis of antigen-specific T lymphocytes

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

P304

681-688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI0214522

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Tambussi

Adriano Lazzarin

Giuseppe Pantaleo

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11877476

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

150896

http://www.w3.org/2001/XMLSchema#string